Lorazepam


Aphena Pharma Solutions - Tennessee, Llc
Human Prescription Drug
NDC 71610-229
Lorazepam is a human prescription drug labeled by 'Aphena Pharma Solutions - Tennessee, Llc'. National Drug Code (NDC) number for Lorazepam is 71610-229. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Lorazepam drug includes Lorazepam - 1 mg/1 . The currest status of Lorazepam drug is Active.

Drug Information:

Drug NDC: 71610-229
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Lorazepam
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Lorazepam
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Aphena Pharma Solutions - Tennessee, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:LORAZEPAM - 1 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 24 Mar, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA203572
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Aphena Pharma Solutions - Tennessee, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:197901
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
NUI:N0000175694
M0002356
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:O26FZP769L
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Benzodiazepine [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Benzodiazepines [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Benzodiazepine [EPC]
Benzodiazepines [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.
DEA Schedule:CIV
This is the assigned DEA Schedule number as reported by the labeler. Values are CI, CII, CIII, CIV, and CV.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
71610-229-1515 TABLET in 1 BOTTLE (71610-229-15)01 Feb, 2019N/ANo
71610-229-3030 TABLET in 1 BOTTLE (71610-229-30)01 Feb, 2019N/ANo
71610-229-4545 TABLET in 1 BOTTLE (71610-229-45)01 Feb, 2019N/ANo
71610-229-5360 TABLET in 1 BOTTLE (71610-229-53)01 Feb, 2019N/ANo
71610-229-5575 TABLET in 1 BOTTLE (71610-229-55)01 Feb, 2019N/ANo
71610-229-6090 TABLET in 1 BOTTLE (71610-229-60)01 Feb, 2019N/ANo
71610-229-70120 TABLET in 1 BOTTLE (71610-229-70)01 Feb, 2019N/ANo
71610-229-75150 TABLET in 1 BOTTLE (71610-229-75)01 Feb, 2019N/ANo
71610-229-80180 TABLET in 1 BOTTLE (71610-229-80)01 Feb, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Lorazepam lorazepam lorazepam lorazepam anhydrous lactose magnesium stearate cellulose, microcrystalline polacrilin potassium white to off white flat-faced beveled edge u33

Drug Interactions:

Clinically significant drug interactions the concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the cns that control respiration. benzodiazepines interact at gabaa sites and opioids interact primarily at mu receptors. when benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. the benzodiazepines, including lorazepam, produce increased cns-depressant effects when administered with other cns depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. concomitant use of clozapine and lorazepam may produce marked sedation, excessive saliva
tion, hypotension, ataxia, delirium, and respiratory arrest. concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced clearance of lorazepam. lorazepam dosage should be reduced to approximately 50% when coadministered with valproate. concurrent administration of lorazepam with probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. lorazepam dosage needs to be reduced by approximately 50% when coadministered with probenecid. the effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. administration of theophylline or aminophylline may reduce the sedative effects of benzodiazepines, including lorazepam.

Boxed Warning:

Warning: risks from concomitant use with opioids concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death (see warnings ; precautions , clinically significant drug interactions ). • reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. • limit dosages and durations to the minimum required. • follow patients for signs and symptoms of respiratory depression and sedation.

Indications and Usage:

Indications and usage lorazepam tablets usp are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of lorazepam tablets usp in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient.

Warnings:

Warnings concomitant use of benzodiazepines, including lorazepam, and opioids may result in profound sedation, respiratory depression, coma, and death. because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. if a decision is made to prescribe lorazepam concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. in patients already receiving an opioid analgesic, prescribe a lower initial dose of lorazepam than indicated in the absence of an opioid and titrate based on clinical response. if an opioid is initiated in a patient already taking lorazepam, prescribe a lower initial dose of
the opioid and titrate based upon clinical response. advise both patients and caregivers about the risks of respiratory depression and sedation when lorazepam is used with opioids. advice patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see precautions , clinically significant drug interactions ). pre-existing depression may emerge or worsen during use of benzodiazepines including lorazepam. lorazepam is not recommended for use in patients with a primary depressive disorder or psychosis. use of benzodiazepines, including lorazepam, both used alone and in combination with other cns depressants, may lead to potentially fatal respiratory depression. (see precautions , clinically significant drug interactions. ) use of benzodiazepines, including lorazepam, may lead to physical and psychological dependence. as with all patients on cns-depressant drugs, patients receiving lorazepam should be warned not to operate dangerous machinery or motor vehicles and that their tolerance for alcohol and other cns depressants will be diminished. physical and psychological dependence the use of benzodiazepines, including lorazepam, may lead to physical and psychological dependence. the risk of dependence increases with higher doses and longer term use and is further increased in patients with a history of alcoholism or drug abuse or in patients with significant personality disorders. the dependence potential is reduced when lorazepam is used at the appropriate dose for short-term treatment. addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving lorazepam or other psychotropic agents. in general, benzodiazepines should be prescribed for short periods only (e.g., 2 to 4 weeks). extension of the treatment period should not take place without reevaluation of the need for continued therapy. continuous long-term use of product is not recommended. withdrawal symptoms (e.g., rebound insomnia) can appear following cessation of recommended doses after as little as one week of therapy. abrupt discontinuation of product should be avoided and a gradual dosage-tapering schedule followed after extended therapy. abrupt termination of treatment may be accompanied by withdrawal symptoms. symptoms reported following discontinuation of benzodiazepines include headache, anxiety, tension, depression, insomnia, restlessness, confusion, irritability, sweating, rebound phenomena, dysphoria, dizziness, derealization, depersonalization, hyperacusis, numbness/tingling of extremities, hypersensitivity to light, noise, and physical contact/perceptual changes, involuntary movements, nausea, vomiting, diarrhea, loss of appetite, hallucinations/delirium, convulsions/seizures, tremor, abdominal cramps, myalgia, agitation, palpitations, tachycardia, panic attacks, vertigo, hyperreflexia, short-term memory loss, and hyperthermia. convulsions/seizures may be more common in patients with pre­-existing seizure disorders or who are taking other drugs that lower the convulsive threshold such as antidepressants. there is evidence that tolerance develops to the sedative effects of benzodiazepines. lorazepam may have abuse potential, especially in patients with a history of drug and/or alcohol abuse.

Dosage and Administration:

Dosage and administration lorazepam tablets are administered orally. for optimal results, dose, frequency of administration, and duration of therapy should be individualized according to patient response. to facilitate this, 0.5 mg, 1 mg, and 2 mg tablets are available. the usual range is 2 to 6 mg/day given in divided doses, the largest dose being taken before bedtime, but the daily dosage may vary from 1 to 10 mg/day. for anxiety, most patients require an initial dose of 2 to 3 mg/day given b.i.d. or t.i.d. for insomnia due to anxiety or transient situational stress, a single daily dose of 2 mg to 4 mg may be given, usually at bedtime. for elderly or debilitated patients, an initial dosage of 1 to 2 mg/day in divided doses is recommended, to be adjusted as needed and tolerated. the dosage of lorazepam tablets should be increased gradually when needed to help avoid adverse effects. when higher dosage is indicated, the evening dose should be increased before the daytime doses.

Contraindications:

Contraindications lorazepam tablets are contraindicated in patients with - hypersensitivity to benzodiazepines or to any components of the formulation. - acute narrow-angle glaucoma.

Adverse Reactions:

Adverse reactions most adverse reactions to benzodiazepines, including cns effects and respiratory depression, are dose dependent, with more severe effects occurring with high doses. in a sample of about 3500 patients treated for anxiety, the most frequent adverse reaction to lorazepam was sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%). the incidence of sedation and unsteadiness increased with age. other adverse reactions to benzodiazepines, including lorazepam are fatigue, drowsiness, amnesia, memory impairment, confusion, disorientation, depression, unmasking of depression, disinhibition, euphoria, suicidal ideation/attempt, ataxia, asthenia, extrapyramidal symptoms, convulsions/seizures tremor, vertigo, eye-function/visual disturbance (including diplopia and blurred vision), dysarthria/slurred speech, change in libido, impotence, decreased orgasm; headache, coma; respiratory depression, apnea, worsening of sleep apnea, worsening of obstructi
ve pulmonary disease; gastrointestinal symptoms including nausea, change in appetite, constipation, jaundice, increase in bilirubin, increase in liver transaminases, increase in alkaline phosphatase; hypersensitivity reactions, anaphylacticoid reactions; dermatological symptoms, allergic skin reactions, alopecia; siadh, hyponatremia; thrombocytopenia, agranulocytosis, pancytopenia; hypothermia; and autonomic manifestations. paradoxical reactions, including anxiety, excitation, agitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations may occur. small decreases in blood pressure and hypotension may occur but are usually not clinically significant, probably being related to the relief of anxiety produced by lorazepam.

Drug Interactions:

Clinically significant drug interactions the concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the cns that control respiration. benzodiazepines interact at gabaa sites and opioids interact primarily at mu receptors. when benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. the benzodiazepines, including lorazepam, produce increased cns-depressant effects when administered with other cns depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. concomitant use of clozapine and lorazepam may produce marked sedation, excessive saliva
tion, hypotension, ataxia, delirium, and respiratory arrest. concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced clearance of lorazepam. lorazepam dosage should be reduced to approximately 50% when coadministered with valproate. concurrent administration of lorazepam with probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. lorazepam dosage needs to be reduced by approximately 50% when coadministered with probenecid. the effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. administration of theophylline or aminophylline may reduce the sedative effects of benzodiazepines, including lorazepam.

Use in Pregnancy:

Pregnancy reproductive studies in animals were performed in mice, rats, and two strains of rabbits. occasional anomalies (reduction of tarsals, tibia, metatarsals, malrotated limbs, gastroschisis, malformed skull, and microphthalmia) were seen in drug-treated rabbits without relationship to dosage. although all of these anomalies were not present in the concurrent control group, they have been reported to occur randomly in historical controls. at doses of 40 mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits which was not seen at lower doses. the clinical significance of the above findings is not known. however, an increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during the first trimester of pregnancy has been suggested in several studies. because the use of these drugs is rarely a matter of urgency, the use of lorazepam during this period should be avoided.
the possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. patients should be advised that if they become pregnant, they should communicate with their physician about the desirability of discontinuing the drug. in humans, blood levels obtained from umbilical cord blood indicate placental transfer of lorazepam and lorazepam glucuronide. infants of mothers who ingested benzodiazepines for several weeks or more preceding delivery have been reported to have withdrawal symptoms during the postnatal period. symptoms such as hypoactivity, hypotonia, hypothermia, respiratory depression, apnea, feeding problems, and impaired metabolic response to cold stress have been reported in neonates born of mothers who have received benzodiazepines during the late phase of pregnancy or at delivery.

Geriatric Use:

Geriatric use clinical studies of lorazepam generally were not adequate to determine whether subjects aged 65 and over respond differently than younger subjects; however, the incidence of sedation and unsteadiness was observed to increase with age (see adverse reactions ). age does not appear to have a significant effect on lorazepam kinetics (see clinical pharmacology ). clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal impairment, should be considered. greater sensitivity (e.g., sedation) of some older individuals cannot be ruled out. in general, dose selection for an elderly patient should be cautious, and lower doses may be sufficient in these patients (see dosage and administration ).

Overdosage:

Overdosage in postmarketing experience, overdose with lorazepam has occurred predominantly in combination with alcohol and/or other drugs. therefore, in the management of overdosage, it should be borne in mind that multiple agents may have been taken. symptoms overdosage of benzodiazepines is usually manifested by varying degrees of central nervous system depression ranging from drowsiness to coma. in mild cases, symptoms include drowsiness, mental confusion, paradoxical reactions, dysarthria and lethargy. in more serious cases, and especially when other drugs or alcohol were ingested, symptoms may include ataxia, hypotonia, hypotension, cardiovascular depression, respiratory depression, hypnotic state, coma, and death. management general supportive and symptomatic measures are recommended; vital signs must be monitored and the patient closely observed. when there is a risk of aspiration, induction of emesis is not recommended. gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients. administration of activated charcoal may also limit drug absorption. hypotension, though unlikely, usually may be controlled with norepinephrine bitartrate injection. lorazepam is poorly dialyzable. lorazepam glucuronide, the inactive metabolite, may be highly dialyzable. the benzodiazepine antagonist flumazenil may be used in hospitalized patients as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. the prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. the complete flumazenil package insert including contraindications , warnings , and precautions should be consulted prior to use.

Description:

Description lorazepam, an antianxiety agent, has the chemical formula, 7-chloro-5-( o -chlorophenyl)-1,3-dihydro-3-hydroxy-2 h -1,4-benzodiazepin-2-one: it is a nearly white powder almost insoluble in water. each lorazepam tablet usp, to be taken orally, contains 0.5 mg, 1 mg, or 2 mg of lorazepam usp. the inactive ingredients present are anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacriline potassium. chemical-structure

Clinical Pharmacology:

Clinical pharmacology studies in healthy volunteers show that in single high doses lorazepam has a tranquilizing action on the central nervous system with no appreciable effect on the respiratory or cardiovascular systems. lorazepam is readily absorbed with an absolute bioavailability of 90 percent. peak concentrations in plasma occur approximately 2 hours following administration. the peak plasma level of lorazepam from a 2 mg dose is approximately 20 ng/ml. the mean half-life of unconjugated lorazepam in human plasma is about 12 hours and for its major metabolite, lorazepam glucuronide, about 18 hours. at clinically relevant concentrations, lorazepam is approximately 85% bound to plasma proteins. lorazepam is rapidly conjugated at its 3-hydroxy group into lorazepam glucuronide which is then excreted in the urine. lorazepam glucuronide has no demonstrable cns activity in animals. the plasma levels of lorazepam are proportional to the dose given. there is no evidence of accumulation of
lorazepam on administration up to six months. studies comparing young and elderly subjects have shown that advancing age does not have a significant effect on the pharmacokinetics of lorazepam. however, in one study involving single intravenous doses of 1.5 to 3 mg of lorazepam injection, mean total body clearance of lorazepam decreased by 20% in 15 elderly subjects of 60 to 84 years of age compared to that in 15 younger subjects of 19 to 38 years of age.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis and mutagenesis no evidence of carcinogenic potential emerged in rats during an 18-month study with lorazepam. no studies regarding mutagenesis have been performed.

How Supplied:

How supplied lorazepam tablets usp are available in the following dosage strengths: 0.5 mg, white to off-white, round, flat-faced beveled edge tablets debossed with “u32” on one side and plain on other side. bottles of 10 ndc 13107-083-11 bottles of 100 ndc 13107-083-01 bottles of 500 ndc 13107-083-05 bottles of 1000 ndc 13107-083-99 1 mg, white to off-white, round, flat-faced beveled edge tablets debossed with “u33” on one side and bisect on other side. bottles of 10 ndc 13107-084-11 bottles of 100 ndc 13107-084-01 bottles of 500 ndc 13107-084-05 bottles of 1000 ndc 13107-084-99 2 mg, white to off-white, round flat-faced beveled edge tablets debossed with a bisect separating “u” and “34” on one side and “2” on the other side. bottles of 10 ndc 13107-085-11 bottles of 100 ndc 13107-085-01 bottles of 500 ndc 13107-085-05 bottles of 1000 ndc 13107-085-99 dispense in a tight, light-resistant container as described in the usp. store at 20Â
°c to 25°c (68°to 77°f). [see usp controlled room temperature.] manufactured by: aurolife pharma llc dayton, nj 08810 manufactured for: aurobindo pharma usa, inc. dayton, nj 08810 revised:11/2017 medication guide lorazepam tablets, usp civ what is the most important information i should know about lorazepam? lorazepam is a benzodiazepine medicine. taking benzodiazepines with opioid medicines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death. lorazepam can make you sleepy or dizzy, and can slow your thinking and motor skills. o do not drive, operate heavy machinery, or do other dangerous activities until you know how lorazepam affects you. o do not drink alcohol or take other drugs that may make you sleepy or dizzy while taking lorazepam without first talking to your healthcare provider. when taken with alcohol or drugs that cause sleepiness or dizziness, lorazepam may make your sleepiness or dizziness much worse. do not take more lorazepam than prescribed. what is lorazepam? lorazepam is a prescription medicine used: o to treat anxiety disorders o for the short-term relief of the symptoms of anxiety or anxiety that can happen with symptoms of depression lorazepam is a federal controlled substance (c-iv) because it can be abused or lead to dependence. keep lorazepam in a safe place to prevent misuse and abuse. selling or giving away lorazepam may harm others, and is against the law. tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines or street drugs. it is not known if lorazepam is safe and effective in children less than 12 years of age. it is not known if lorazepam is safe and effective for use for longer than 4 months. do not take lorazepam if you: are allergic to lorazepam, other benzodiazepines, or any of the ingredients in lorazepam. see the end of this medication guide for a complete list of ingredients in lorazepam. before you take lorazepam, tell your healthcare provider about all of your medical conditions, including if you: have or have had depression, mood problems, or suicidal thoughts or behavior have a history of drug or alcohol abuse or addiction have lung disease or breathing problems (such as copd, sleep apnea syndrome) have liver or kidney problems have or have had seizures are pregnant or plan to become pregnant. lorazepam may harm your unborn baby. you and your healthcare provider should decide if you should take lorazepam while you are pregnant. are breastfeeding or plan to breastfeed. lorazepam passes into your breast milk and may harm your baby. talk to your healthcare provider about the best way to feed your baby if you take lorazepam. you should not breastfeed while taking lorazepam tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. taking lorazepam with certain other medicines can cause side effects or affect how well lorazepam or the other medicines work. do not start or stop other medicines without talking to your healthcare provider. how should i take lorazepam? take lorazepam exactly as your healthcare provider tells you to take it. your healthcare provider will tell you how much lorazepam to take and when to take it. if you take too much lorazepam, call your healthcare provider or go to the nearest hospital emergency room right away. what should i avoid while taking lorazepam? lorazepam can cause you to be drowsy. do not drive a car or operate heavy machinery until you know how lorazepam affects you. you should not drink alcohol while taking lorazepam. drinking alcohol can increase your chances of having serious side effects. what are the possible side effects of lorazepam? lorazepam may cause serious side effects, including: see “what is the most important information i should know about lorazepam?” depression. pre-existing depression may emerge or worsen during use of benzodiazepines including lorazepam. abuse and dependence. taking lorazepam can cause physical and psychological dependence. physical and psychological dependence is not the same as drug addiction. your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction. withdrawal symptoms. you may have withdrawal symptoms if you stop taking lorazepam suddenly. withdrawal symptoms can be serious and include seizures. mild withdrawal symptoms include a depressed mood and trouble sleeping. talk to your healthcare provider about slowly stopping lorazepam to avoid withdrawal symptoms. the most common side effects of lorazepam include: sedation dizziness weakness unsteadiness these are not all the possible side effects of lorazepam. call your doctor for medical advice about side effects. you may report side effects to fda at 1-800-fda-1088. how should i store lorazepam? store lorazepam in a tightly closed container at 77°f (25°c); excursions permitted to 59° to 86°f (15° to 30°c). keep lorazepam and all medicines out of the reach of children. general information about the safe and effective use of lorazepam. medicines are sometimes prescribed for purposes other than those listed in a medication guide. do not use lorazepam for a condition for which it was not prescribed. do not give lorazepam to other people, even if they have the same symptoms that you have. it may harm them. you can ask your pharmacist or healthcare provider for information about lorazepam that is written for health professionals. what are the ingredients in lorazepam? active ingredient: lorazepam inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose and polacrilin potassium. this medication guide has been approved by the u.s. food and drug administration manufactured by: aurolife pharma llc dayton, nj 08810 manufactured for: aurobindo pharma usa, inc. dayton, nj 08810 revised:11/2017

Information for Patients:

Information for patients to assure the safe and effective use of lorazepam, patients should be informed that, since benzodiazepines may produce psychological and physical dependence, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug. essential laboratory tests some patients on lorazepam have developed leukopenia, and some have had elevations of ldh. as with other benzodiazepines, periodic blood counts and liver function tests are recommended for patients on long-term therapy.

Package Label Principal Display Panel:

Principal display panel - 1 mg ndc 71610-229 - lorazepam, usp 1 mg - rx only bottle label 1 mg


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.